In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo

Ann Intern Med. 2024 Feb 6. doi: 10.7326/J23-0122. Online ahead of print.ABSTRACTFord AC, Wright-Hughes A, Alderson SL, et al; ATLANTIS trialists. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:1773-1785. 37858323.PMID:38315998 | DOI:10.7326/J23-0122

Source: Annals of Internal Medicine - February 5, 2024 Category: Internal Medicine Authors: Tanvi Gupta Brooks D Cash Source Type: research